Sanofi (SAN.PA)

Exchange: Euronext Paris
Currency: EUR

 
Price: 88.44 (Close)

Summary

 

52 Week range 200d Moving Avg. Beta
71.74 – 95.06 85.20 0.46
Dividend Dividend Yield Ex-Dividend date
3.07 3.38% 2019-05-09
P/E Ratio Latest EPS DGR 3 years
39.39 2.25 2.06%
Overvalued
Low
Very low Volatility
High
Slow
Dividend Growth
Fast

Profile

Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, for hematologic malignancies; and Zaltrap, for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has an alliance with Verily Life Sciences LLC; and agreement with Happify Health. Sanofi was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

 

Sector: Industry:
Healthcare Drug Manufacturers – Major

Environment, Social and Governance (ESG) Ratings

Total ESG Score

32 – 48 percentile

Environment

7 – 7 percentile

Social

20 – 7 percentile

Governance

17 – 7 percentile

Controversy level

3

Sanofi (SAN.PA) Valuation


Sanofi current dividend yield of 3.38% is -10% below its 5-year average. The 5-year average dividend yield is 3.77% (see red-line in chart). This indicates the stock looks overvalued today.

Sanofi (SAN.PA) Performance

The chart below displays the total price return(%) of Sanofi for different periods:

 

Sanofi (SAN.PA) Total Return

The chart below displays the (CAGR) total return (%) including all dividends paid of Sanofi for different periods:

 


Dividend Scorecard

Dividend Yield (TTM) Annual Payout Payout Ratio Dividend growth
3.38 3.07 136.44% 24 Years

 

Dividend Growth Summary

3 Year Growth Rate (CAGR) 2.06%
5 Year Growth Rate (CAGR) 1.81%
10 Year Growth Rate (CAGR) 3.88%

Dividend Growth Rates History

Year Payout Amount Annual Payout Growth (YoY)
2019 3.070 1.3%
2018 3.030 2.4%
2017 2.960 1.0%
2016 2.930 2.8%
2015 2.850 1.8%
2014 2.800 1.1%
2013 2.770 4.5%
2012 2.650 6.0%
2011 2.500 4.2%
2010 2.400 9.1%
2009 2.200 6.3%
2008 2.070 18.3%
2007 1.750 -4.4%
2006 1.830 23.6%
2005 1.480 45.1%

Sanofi (SAN.PA) Dividend Payment History